RecruitingPhase 1NCT06545331
Study of XB010 in Subjects With Solid Tumors
Sponsor: Exelixis
Washington D.C., DC · +15 more sites
Breast Cancer clinical trials in Washington D.C., DC
20 recruiting breast cancer studies with a site in Washington D.C., DC.
All trials in Washington D.C., DC · All Breast Cancer trials
RecruitingPhase 3NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Sponsor: Merck Sharp & Dohme LLC
Washington D.C., DC · +38 more sites
RecruitingPhase 1NCT07310420
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Sponsor: TerSera Therapeutics LLC
Washington D.C., DC · +25 more sites
RecruitingPhase 3NCT07174336
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Sponsor: Eli Lilly and Company
Washington D.C., DC · +128 more sites
RecruitingPhase 3NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Sponsor: Relay Therapeutics, Inc.
Washington D.C., DC · +51 more sites
RecruitingPhase 1NCT05983432
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Sponsor: SystImmune Inc.
Washington D.C., DC · +21 more sites
RecruitingPhase 2NCT06923527
Circulating Tumor DNA
Sponsor: Yale University
Washington D.C., DC · +6 more sites
RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Washington D.C., DC · +173 more sites
RecruitingPhase 3NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor: NRG Oncology
Washington D.C., DC · +1223 more sites
RecruitingPhase 1NCT07182149
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Sponsor: Normunity AccelCo, Inc.
Washington D.C., DC · +17 more sites
RecruitingPhase 3NCT05232916
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Sponsor: Greenwich LifeSciences, Inc.
Washington D.C., DC · +50 more sites
RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Washington D.C., DC · +825 more sites
RecruitingPhase 3NCT06748222
E-Mindfulness Approaches for Living After Breast Cancer
Sponsor: NRG Oncology
Washington D.C., DC · +378 more sites
RecruitingPhase 2NCT05467891
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Sponsor: Oana Danciu
Washington D.C., DC · +20 more sites
RecruitingPhase not listedNCT06551116
QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
Washington D.C., DC · +34 more sites
RecruitingNot applicableNCT07228000
Bundled Cancer Screening and Genetic Services Navigation
Sponsor: Georgetown University
Washington D.C., DC · +1 more sites
RecruitingPhase 3NCT04852887
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Sponsor: NRG Oncology
Washington D.C., DC · +809 more sites
RecruitingPhase 3NCT06435429
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Sponsor: Jazz Pharmaceuticals
Washington D.C., DC · +46 more sites
RecruitingPhase 1NCT04389281
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Sponsor: Immunolight, LLC
Washington D.C., DC · +3 more sites
RecruitingPhase 1 / Phase 2NCT05256745
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Sponsor: Georgetown University
Washington D.C., DC · +1 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.